- Active not recruitingPHASE3
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
This study looks at new ways to treat advanced non-small cell lung cancer with a specific genetic change. It aims to see if combining a drug called ramucirumab with existing treatments like erlotinib, gefitinib, or osimertinib can work better than current approaches.
For: Metastatic Non-Small Cell Lung CancerUnited States · Canada · France - RecruitingPHASE2, PHASE3
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
This study looks at a new drug, telisotuzumab adizutecan, for a type of lung cancer called non-small cell lung cancer. It compares the new drug to standard treatments to see how safe it is and how well it works in adults with advanced lung cancer.
For: Non-Small Cell Lung CancerUnited States · Australia · Austria - Active not recruitingPHASE3
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)
This study is for cancer patients who are already taking osimertinib (Tagrisso) in another AstraZeneca study and are still benefiting from it. It allows them to keep taking the drug to see if it continues to help.
For: CancerChina · France · Japan - Active not recruitingPHASE3
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
This study looks at a new combination of medicines, savolitinib and osimertinib, for people with a type of lung cancer that has gotten worse after treatment with osimertinib. It compares this new combination to standard chemotherapy to see if it works better and is safe.
For: Carcinoma · Non-Small-Cell LungUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This study is looking at two new drug combinations, amivantamab and lazertinib, compared to a standard drug, osimertinib, for people in the UK with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation).
For: Carcinoma, Non-Small-Cell LungUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
This study is looking at new combinations of medicines for advanced lung or breast cancer. We want to see if they are safe, how much medicine gets into the body, and if they show early signs of working. It's for adults with certain types of advanced cancer.
For: Lung Cancer · Breast CancerUnited States · Australia · Canada - RecruitingPHASE1
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
This study looks at a new drug, BNT116, for advanced lung cancer. It explores if BNT116 is safe, how much to give, and how well it works when used alone or with other treatments for different types of non-small cell lung cancer.
For: Non-Small Cell Lung CancerUnited States · Australia · Germany - Active not recruitingPHASE3
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
This study looks at new ways to treat a type of lung cancer before surgery. We're testing a drug called osimertinib, either alone or with chemotherapy, against chemotherapy by itself. The goal is to see if these new treatments can help more people with resectable non-small cell lung cancer.
For: Non-Small Cell Lung CancerUnited States · Austria · Brazil - Active not recruitingPHASE3
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
This study looks at combining a drug called osimertinib with chemotherapy for a type of lung cancer. It wants to see if this combination works better than osimertinib alone for patients with a specific genetic change in their cancer, hoping to delay the cancer getting worse.
For: Non-Small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE2
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)
This study explored a new combination of medicines, tepotinib and osimertinib, for people with a specific type of advanced lung cancer. It looked at whether this combination could shrink tumours, was safe, and how the body handled the drugs after their initial treatment stopped working.
For: Non-small Cell Lung CancerUnited States · Belgium · China - Active not recruitingPHASE2
Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone
This study allows people already getting certain cancer treatments through a Novartis trial to continue their treatment. It looks at how safe and effective these treatments are over a longer time for people with advanced solid tumours, giving them ongoing access to care.
For: Advanced Solid Tumors Which Are cMET-dependentUnited States · Belgium · Canada - Active not recruitingPHASE1, PHASE2
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
This study is looking into a new drug, MCLA-129, for some advanced cancers like lung or stomach cancer. It will see how safe and effective it is, both by itself and with other treatments. It's for people who haven't responded to previous treatments.
For: Non-Small Cell Lung Cancer Metastatic · Gastric Cancer · Esophageal Squamous Cell CarcinomaUnited States · Belgium · France - RecruitingPHASE3
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This study looks at new treatments for a type of lung cancer where standard treatment has stopped working. It compares a drug called Dato-DXd, alone or with osimertinib, against usual chemotherapy to see which helps patients live longer without their cancer getting worse.
For: Metastatic Non-small Cell Lung CancerUnited States · Australia · Belgium - Active not recruitingPHASE2
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
This study looks at a new combination of two drugs, osimertinib and savolitinib, for people with a certain type of advanced lung cancer. It's for patients whose cancer has grown worse after already taking osimertinib, to see if the new combination can help.
For: CarcinomaUnited States · Brazil · Canada - Active not recruitingPHASE2
Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC
This study compares using a drug called osimertinib alone, or osimertinib with focused radiation (SRS), for lung cancer that has spread to the brain. It's for people whose lung cancer has a specific genetic change (EGFR positive) and haven't had previous treatment for it.
For: Lung Cancer Non-small Cell Stage IV · Brain MetastasesCanada - Active not recruitingPHASE2
Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study
This study looks at whether it's safe and effective to continue a lung cancer drug called osimertinib (Tagrisso) while also having radiotherapy. It focuses on people with a specific type of lung cancer that has a particular genetic change.
For: NSCLC · EGFR Positive Non-small Cell Lung Cancer · OligoprogressionGermany - Active not recruitingPHASE3
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
This study looks at a drug called osimertinib for people with a certain type of early-stage lung cancer after surgery. We want to see if it helps prevent the cancer from coming back compared to a dummy drug (placebo).
For: Non-Small Cell Lung CancerUnited States · Argentina · Brazil